Nothing Special   »   [go: up one dir, main page]

MX2015005633A - Terapia adyuvante con inhibidores de quinasa de la familia tec. - Google Patents

Terapia adyuvante con inhibidores de quinasa de la familia tec.

Info

Publication number
MX2015005633A
MX2015005633A MX2015005633A MX2015005633A MX2015005633A MX 2015005633 A MX2015005633 A MX 2015005633A MX 2015005633 A MX2015005633 A MX 2015005633A MX 2015005633 A MX2015005633 A MX 2015005633A MX 2015005633 A MX2015005633 A MX 2015005633A
Authority
MX
Mexico
Prior art keywords
kinase inhibitor
family kinase
tec family
adjuvant therapy
inhibitor adjuvant
Prior art date
Application number
MX2015005633A
Other languages
English (en)
Inventor
Joseph J Buggy
Tarak Mody
Richard B Love
John C Byrd
Betty Chang
Jason A Dubovsky
Natarajan Muthusamy
Amy Jo Johnson
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50628113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015005633(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Publication of MX2015005633A publication Critical patent/MX2015005633A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

En la presente descripción se describen métodos y composiciones que comprenden un inhibidor de quinasa de la familia TEC covalente para usar en la terapia adyuvante que incluye la terapia adyuvante para el cáncer, la vacunación y el tratamiento de trastornos inmunes e infecciones patógenas.
MX2015005633A 2012-11-02 2013-11-01 Terapia adyuvante con inhibidores de quinasa de la familia tec. MX2015005633A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722107P 2012-11-02 2012-11-02
US201361785868P 2013-03-14 2013-03-14
PCT/US2013/068132 WO2014071231A1 (en) 2012-11-02 2013-11-01 Tec family kinase inhibitor adjuvant therapy

Publications (1)

Publication Number Publication Date
MX2015005633A true MX2015005633A (es) 2016-02-03

Family

ID=50628113

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015005633A MX2015005633A (es) 2012-11-02 2013-11-01 Terapia adyuvante con inhibidores de quinasa de la familia tec.
MX2021003018A MX2021003018A (es) 2012-11-02 2015-05-04 Terapia adyuvante con inhibidores de quinasa de la familia tec.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021003018A MX2021003018A (es) 2012-11-02 2015-05-04 Terapia adyuvante con inhibidores de quinasa de la familia tec.

Country Status (22)

Country Link
US (4) US9717731B2 (es)
EP (1) EP2914263A4 (es)
JP (3) JP2015536950A (es)
KR (1) KR20150080592A (es)
CN (2) CN111329989A (es)
AU (3) AU2013337663A1 (es)
BR (1) BR112015010059A2 (es)
CA (1) CA2890111A1 (es)
CL (1) CL2015001147A1 (es)
CR (1) CR20150242A (es)
DO (1) DOP2015000098A (es)
EA (1) EA201590822A1 (es)
HK (1) HK1214508A1 (es)
IL (1) IL238548A0 (es)
MX (2) MX2015005633A (es)
NI (1) NI201500062A (es)
PE (1) PE20151604A1 (es)
PH (1) PH12015500985A1 (es)
SG (1) SG11201503459SA (es)
TN (1) TN2015000170A1 (es)
TW (1) TW201427664A (es)
WO (1) WO2014071231A1 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CN102482277B (zh) 2009-05-05 2017-09-19 达纳-法伯癌症研究所有限公司 表皮生长因子受体抑制剂及治疗障碍的方法
KR101580714B1 (ko) 2010-06-03 2016-01-04 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도
WO2012021444A1 (en) 2010-08-10 2012-02-16 Avila Therapeutics, Inc. Besylate salt of a btk inhibitor
EP3034509B1 (en) 2010-10-26 2020-04-22 Mars, Incorporated Arginase inhibitors as therapeutics
US8975249B2 (en) 2010-11-01 2015-03-10 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
JP5956999B2 (ja) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
US8796255B2 (en) 2010-11-10 2014-08-05 Celgene Avilomics Research, Inc Mutant-selective EGFR inhibitors and uses thereof
CA2853498A1 (en) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
MX356179B (es) 2012-03-15 2018-05-17 Celgene Avilomics Res Inc Sales de un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
ES2880109T3 (es) 2012-03-15 2021-11-23 Celgene Car Llc Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
MX2015005633A (es) 2012-11-02 2016-02-03 Pharmacyclics Inc Terapia adyuvante con inhibidores de quinasa de la familia tec.
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
PE20151274A1 (es) 2013-02-08 2015-09-12 Celgene Avilomics Res Inc Inhibidores de erk y sus usos
US9974774B2 (en) 2013-07-26 2018-05-22 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
EP3027192A4 (en) * 2013-08-02 2017-03-22 Pharmacyclics, LLC Methods for the treatment of solid tumors
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
TWI617309B (zh) * 2013-10-25 2018-03-11 製藥公司 使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
US10314842B2 (en) * 2013-12-02 2019-06-11 Cornell University Methods for treating B cell proliferative disorders
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2015187848A1 (en) * 2014-06-04 2015-12-10 Sampath Deepa Hdac inhibitor and btk inhibitor combinations
US20150361504A1 (en) * 2014-06-13 2015-12-17 Pharmacyclics Llc Biomarker for predicting response of cll to treatment with a btk inhibitor
WO2016010961A1 (en) * 2014-07-15 2016-01-21 Abbvie Inc. Enzyme occupancy assay
CA2954725A1 (en) * 2014-07-25 2016-01-28 Northeastern University Biopolymer-nanoparticle composite implant for tumor cell tracking
ES2741785T3 (es) 2014-08-13 2020-02-12 Celgene Car Llc Formas y composiciones de un inhibidor de ERK
WO2016044774A1 (en) * 2014-09-18 2016-03-24 Pharmacyclics Llc Dendritic cell based vaccine with bruton's tyrosine kinase inhibitor
US20180338993A1 (en) * 2014-12-04 2018-11-29 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016123073A1 (en) 2015-01-26 2016-08-04 Children's Medical Center Corporation Treatment of infectious diseases
KR20170117450A (ko) 2015-02-18 2017-10-23 엔리벡스 테라퓨틱스 리미티드 암 치료를 위한 면역 요법 및 사이토카인 조절 요법의 조합
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
WO2017141243A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
WO2016138542A1 (en) * 2015-02-28 2016-09-01 Cyprus Therapeutics, Inc. Methods for inhibiting tumors and drug resistance
WO2016167236A1 (ja) 2015-04-13 2016-10-20 第一三共株式会社 Ｍｄｍ２阻害剤とｂｔｋ阻害剤との併用治療法
DK3285768T3 (da) 2015-04-21 2021-01-25 Eiger Biopharmaceuticals Inc Farmaceutiske sammensætninger omfattende lonafarnib og ritonavir
CA2982452A1 (en) 2015-04-21 2016-10-27 Enlivex Therapeutics Ltd. Therapeutic pooled blood apoptotic cell preparations and uses thereof
US11554138B2 (en) 2015-07-16 2023-01-17 The University Of Hong Kong Bismuth(III) complexes as adjuvants in the treatment of cancer using platinum-based chemotherapy
CA2994161A1 (en) * 2015-07-31 2017-02-09 Pharmacyclics Llc Bruton's tyrosine kinase inhibitor combinations and uses thereof
ES2913119T3 (es) * 2015-08-12 2022-05-31 Portola Pharm Inc Cerdulatinib para tratar mieloma
LT3368541T (lt) * 2015-10-30 2020-09-25 Calithera Biosciences, Inc. Kompozicijos ir būdai, skirti arginazės aktyvumo inhibavimui
US10736895B2 (en) 2015-12-04 2020-08-11 Portola Pharmaceuticals, Inc. Cerdulatinib for treating hematological cancers
US10953072B2 (en) 2016-02-19 2021-03-23 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection with interferon lambda
EP3318276A1 (en) * 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
CN106405086A (zh) * 2016-09-21 2017-02-15 四川大学华西医院 一种肺癌筛查试剂盒
US20190298772A1 (en) 2016-11-03 2019-10-03 Juno Therapeutics, Inc. Combination therapy of a t cell-based therapy and a btk inhibitor
US11590167B2 (en) 2016-12-03 2023-02-28 Juno Therapeutic, Inc. Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
US10287303B2 (en) 2016-12-22 2019-05-14 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
CN108732280B (zh) * 2017-04-18 2022-07-08 广东东阳光药业有限公司 一种分离检测盐酸达卡他韦及其光学异构体的方法
WO2019014684A1 (en) * 2017-07-14 2019-01-17 Ohio State Innovation Foundation EXPANSION OF IMMUNE CELLS WITH INTERLEUKIN-INDUCIBLE T CELL KINASE-INHIBITING COMPOUNDS
WO2019063958A1 (en) 2017-09-27 2019-04-04 The University Of York BIOCONJUGATION OF POLYPEPTIDES
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
WO2019213184A1 (en) 2018-05-03 2019-11-07 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
US10865198B2 (en) 2018-05-04 2020-12-15 Alexion Pharmaceuticals, Inc. Solid forms of cerdulatinib
CN111110685A (zh) * 2018-10-31 2020-05-08 正大天晴药业集团股份有限公司 一种含伊布替尼的药物组合物及其应用
CA3150343A1 (en) * 2019-09-09 2021-03-18 Hakon Hakonarson COMPOSITIONS AND METHODS OF TREATING DISORDERS ASSOCIATED WITH MALFUNCTION OR LOSS OF CLEC16A
WO2021093790A1 (en) * 2019-11-11 2021-05-20 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric genes
WO2021207716A2 (en) * 2020-04-10 2021-10-14 Ohio State Innovation Foundation Methods and composition for treatment of covid-19 illness requiring hospitalization
WO2021252494A1 (en) * 2020-06-08 2021-12-16 Icahn School Of Medicine At Mount Sinai Use of multi-kinase inhibitors to treat rna virus infections
AU2023250381A1 (en) * 2022-04-05 2024-08-29 Corvus Pharmaceuticals, Inc. Itk inhibitors for increasing th1 cell activity
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1240899A3 (en) 1996-01-23 2004-05-19 Ribapharm, Inc. Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections
EP1254911A1 (en) 1996-10-16 2002-11-06 ICN Pharmaceuticals, Inc. Monocyclic L-nucleosides, analogs and uses thereof
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
EP1118000A1 (en) 1998-09-28 2001-07-25 Diacrin, Inc. Determining resistance to treatment for hepatitis c virus
US6824768B2 (en) 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
CN1355708A (zh) 1999-04-19 2002-06-26 先灵公司 包含利巴韦林与抗氧化剂的hcv联合治疗
EP1227844A2 (en) 1999-10-29 2002-08-07 Pharmacyclics, Inc. Compositions for treating atheroma and neoplastic tissue
WO2001066132A2 (en) 2000-03-09 2001-09-13 Schering Corporation Hiv immune adjuvant therapy
US20020039734A1 (en) 2000-05-18 2002-04-04 Hanrahan Catherine F. Compositions, kits, and methods for identification and modulation of T helper-1 and T helper-2 cells and diseases associated therewith
HUP0301444A3 (en) 2000-10-18 2007-05-29 Schering Corp The use of ribavirin-pegylated interferon alfa for the preparation of pharmaceutical compositions for the treatment of hcv infection
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
GB0116249D0 (en) 2001-07-05 2001-08-29 Imp College Innovations Ltd Methods
BR0312738A (pt) 2002-07-15 2007-06-26 Wyeth Corp processos e composições para a modulação do desenvolvimento e da função de células t auxiliares (th)
WO2004060319A2 (en) 2002-12-30 2004-07-22 3M Innovative Properties Company Immunostimulatory combinations
US20070032457A1 (en) 2003-05-16 2007-02-08 Blatt Lawrence M Combination therapy for cancer treatment
CN1886156A (zh) 2003-09-30 2006-12-27 特莱索恩儿童健康研究院 免疫治疗方法
CA2628397C (en) 2005-11-04 2013-08-20 Novartis Vaccines And Diagnostics S.R.L. Changing th1/th2 balance in split influenza vaccines with adjuvants
US20090197853A1 (en) 2005-11-16 2009-08-06 Pharmacyclics, Inc. Methods and compositions of treating cancer
GB0605521D0 (en) 2006-03-18 2006-04-26 Isis Innovation Adjuvant
KR20090057035A (ko) 2006-08-21 2009-06-03 유나이티드 세러퓨틱스 코오포레이션 바이러스 감염의 치료를 위한 병용 요법
EP2529621B1 (en) * 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US20120065201A1 (en) 2007-03-28 2012-03-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
JP4932940B2 (ja) 2007-11-12 2012-05-16 セラクローン サイエンシーズ， インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
GB0805356D0 (en) 2008-03-25 2008-04-30 Isis Innovation Vaccine adjuvant composition
WO2009140853A1 (en) 2008-05-23 2009-11-26 The University Of Hong Kong Combination therapy for the treatment of influenza
EP2318031A4 (en) 2008-06-03 2012-09-12 Aethlon Medical Inc IMPROVED METHODS AND DEVICES FOR ANTIVIRAL THERAPY
JP2012503619A (ja) 2008-09-26 2012-02-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｈｃｖ感染に対する抗ウイルス治療のための標的としての宿主細胞キナーゼ
WO2010069809A1 (en) 2008-12-18 2010-06-24 F. Hoffmann-La Roche Ag Biomarkers for hcv treatment response
JP2012517478A (ja) 2009-02-12 2012-08-02 バーテックス ファーマシューティカルズ インコーポレイテッド ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、ｈｃｖ組合せ治療剤
MA33323B1 (fr) 2009-04-20 2012-06-01 Genentech Inc Thérapie adjuvante de cancer
US8299070B2 (en) 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
KR101580714B1 (ko) * 2010-06-03 2016-01-04 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도
GB2481611A (en) 2010-06-30 2012-01-04 Statoil Asa Test cell for well fluid assessment
EP2640359A4 (en) * 2010-11-18 2015-11-04 Gen Hospital Corp NEW COMPOSITIONS AND USES OF BLOOD PRESSURE RECIPROCATORS FOR CANCER THERAPY
AU2012275841A1 (en) 2011-06-27 2014-01-16 The Jackson Laboratory Methods and compositions for treatment of cancer and autoimmune disease
WO2013036994A1 (en) 2011-09-16 2013-03-21 Biota Scientific Management Pty Ltd Compounds for the treatment of hcv
WO2013085893A1 (en) 2011-12-05 2013-06-13 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
CA3218491A1 (en) 2012-06-04 2013-12-12 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
MX2015005633A (es) 2012-11-02 2016-02-03 Pharmacyclics Inc Terapia adyuvante con inhibidores de quinasa de la familia tec.

Also Published As

Publication number Publication date
NI201500062A (es) 2016-02-16
SG11201503459SA (en) 2015-06-29
CN104994858A (zh) 2015-10-21
HK1214508A1 (zh) 2016-07-29
BR112015010059A2 (pt) 2017-07-11
MX2021003018A (es) 2021-05-27
KR20150080592A (ko) 2015-07-09
CL2015001147A1 (es) 2015-06-26
AU2018233032A1 (en) 2018-10-11
IL238548A0 (en) 2015-06-30
US20180071293A1 (en) 2018-03-15
TN2015000170A1 (en) 2016-10-03
TW201427664A (zh) 2014-07-16
JP2015536950A (ja) 2015-12-24
PE20151604A1 (es) 2015-11-04
JP2019031506A (ja) 2019-02-28
AU2020220205A1 (en) 2020-09-10
WO2014071231A1 (en) 2014-05-08
US20140134265A1 (en) 2014-05-15
CA2890111A1 (en) 2014-05-08
EP2914263A4 (en) 2016-04-27
US20200147084A1 (en) 2020-05-14
DOP2015000098A (es) 2015-06-30
JP2020183413A (ja) 2020-11-12
EA201590822A1 (ru) 2016-01-29
AU2018233032B2 (en) 2020-05-21
US20140371241A1 (en) 2014-12-18
AU2013337663A1 (en) 2015-06-11
PH12015500985A1 (en) 2015-08-03
US9717731B2 (en) 2017-08-01
CN111329989A (zh) 2020-06-26
EP2914263A1 (en) 2015-09-09
CR20150242A (es) 2015-08-17

Similar Documents

Publication Publication Date Title
TN2015000170A1 (en) Tec family kinase inhibitor adjuvant therapy
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
PH12015502161A1 (en) Therapeutic compounds and compositions
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
NZ707086A (en) Anti-cd40 antibodies and methods of use
EP2563366A4 (en) USE OF PHOSPHOLIPID CONJUGATES FROM SYNTHETIC TLR7 AGONISTS
MX2018001755A (es) Vacuna contra viruela para tratamiento del cancer.
NZ707778A (en) Therapeutic compounds and compositions and their use as pkm2 modulators
MX366899B (es) Nuevos compuestos.
WO2015009726A3 (en) Medical uses of cd38 agonists
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
MX342274B (es) Actividades de la piruvato quinasa m2 (pkm2).
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
MX349004B (es) Nuevos compuestos.
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
EP2934578A4 (en) VACCINES FOR TREATING CANCER AND COMPOSITIONS FOR IMPROVING VACCINE EFFICIENCY
MX365192B (es) Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer.
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
GB2519004A (en) Quinone compounds and their uses for the treatment of cancer